Algernon Pharmaceuticals Inc. C.AGN

DMT stroke trial commences with first patient dosed

[XeniaTechie]

Algernon announces they’ve dosed the first subject in the Phase 1 DMT clinical stroke study. This study is being conducted at the Centre for Human Drug Research in Leiden, Netherlands. The first part of this study will use a single-escalating dose design aimed at identifying a safe and tolerable dose that will not produce psychedelic effects. AGN’s DMT trial also positions them as one of the cheapest psychedelic stocks on the market. https://www.youtube.com/watch?v=BfjAjt1jxuU

[waves1]

There is significant potential here as AGN is taking a new approach to stroke treatment that greatly differs from the previous stroke drug treatments that failed. By focusing on promoting neuroplasticity with DMT, AGN could make a breakthrough here.